According to Teva Pharmaceutical Industries's latest financial reports the company has $3.22 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $3.22 B | 15.17% |
2022-12-31 | $2.80 B | 29.38% |
2021-12-31 | $2.16 B | -0.55% |
2020-12-31 | $2.17 B | 10.23% |
2019-12-31 | $1.97 B | 10.83% |
2018-12-31 | $1.78 B | 85.05% |
2017-12-31 | $0.96 B | -2.53% |
2016-12-31 | $0.98 B | -85.78% |
2015-12-31 | $6.94 B | 212.04% |
2014-12-31 | $2.22 B | 114.45% |
2013-12-31 | $1.03 B | -63.95% |
2012-12-31 | $2.87 B | 162.68% |
2011-12-31 | $1.09 B | -14.64% |
2010-12-31 | $1.28 B | -42.88% |
2009-12-31 | $2.24 B | 17.88% |
2008-12-31 | $1.90 B | -33.67% |
2007-12-31 | $2.87 B | 40.66% |
2006-12-31 | $2.04 B | -7.59% |
2005-12-31 | $2.21 B | 112.49% |
2004-12-31 | $1.04 B | -24.53% |
2003-12-31 | $1.37 B | 31.92% |
2002-12-31 | $1.04 B | 32.33% |
2001-12-31 | $0.79 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Novartis NVS | $13.96 B | 332.80% | ๐จ๐ญ Switzerland |
Pfizer PFE | $12.69 B | 293.37% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | 207.75% | ๐ซ๐ท France |
Merck MRK | $7.09 B | 119.87% | ๐บ๐ธ USA |
AstraZeneca AZN | $5.86 B | 81.65% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $6.35 B | 96.99% | ๐ฌ๐ง UK |
Dr. Reddy's RDY | $0.86 B | -73.06% | ๐ฎ๐ณ India |